THIS CONSTRUCT IS COMPRISED OF RESIDUES 28-419 OF THE FULL-LENGTH PROTEIN. IT WAS EXPRESSED WITH A ...THIS CONSTRUCT IS COMPRISED OF RESIDUES 28-419 OF THE FULL-LENGTH PROTEIN. IT WAS EXPRESSED WITH A PURIFICATION TAG MGSDKIHHHHHHENLYFQG. THE TAG WAS REMOVED WITH TEV PROTEASE LEAVING ONLY A GLYCINE (0) FOLLOWED BY THE TARGET SEQUENCE.
解像度: 1.85→29.604 Å / Num. obs: 66845 / % possible obs: 100 % / 冗長度: 3.8 % / Biso Wilson estimate: 22.6 Å2 / Rmerge(I) obs: 0.093 / Rsym value: 0.093 / Net I/σ(I): 9.4
反射 シェル
Diffraction-ID: 1
解像度 (Å)
冗長度 (%)
Rmerge(I) obs
Mean I/σ(I) obs
Num. measured all
Num. unique all
Rsym value
% possible all
1.85-1.9
3.8
0.67
1.9
18642
4946
0.67
100
1.9-1.95
3.8
0.581
2.2
18011
4776
0.581
100
1.95-2.01
3.8
0.456
2.8
17666
4681
0.456
100
2.01-2.07
3.8
0.36
3.4
17160
4538
0.36
100
2.07-2.14
3.8
0.303
4.1
16615
4382
0.303
100
2.14-2.21
3.8
0.251
4.9
16185
4267
0.251
100
2.21-2.29
3.8
0.207
5.8
15497
4096
0.207
100
2.29-2.39
3.8
0.173
6.8
15011
3952
0.173
100
2.39-2.49
3.8
0.151
7.7
14513
3819
0.151
100
2.49-2.62
3.8
0.124
9.4
13739
3616
0.124
100
2.62-2.76
3.8
0.107
11.1
13096
3441
0.107
100
2.76-2.93
3.8
0.096
12.5
12360
3246
0.096
100
2.93-3.13
3.8
0.076
15
11763
3095
0.076
100
3.13-3.38
3.8
0.065
17.3
10866
2870
0.065
100
3.38-3.7
3.8
0.056
19.7
10010
2647
0.056
100
3.7-4.14
3.8
0.049
21.8
9002
2389
0.049
100
4.14-4.78
3.8
0.052
23.5
7945
2113
0.052
100
4.78-5.85
3.7
0.053
24.6
6655
1784
0.053
100
5.85-8.27
3.7
0.046
25.5
5202
1413
0.046
100
8.27-29.604
3.6
0.043
26.6
2754
774
0.043
97.8
-
位相決定
位相決定
手法: 多波長異常分散
-
解析
ソフトウェア
名称
バージョン
分類
NB
REFMAC
5.5.0053
精密化
PHENIX
精密化
SHELX
位相決定
MolProbity
3beta29
モデル構築
SCALA
3.2.5
データスケーリング
PDB_EXTRACT
3.006
データ抽出
MAR345
CCD
データ収集
MOSFLM
データ削減
SHELXD
位相決定
autoSHARP
位相決定
精密化
構造決定の手法: 多波長異常分散 / 解像度: 1.85→29.604 Å / Cor.coef. Fo:Fc: 0.967 / Cor.coef. Fo:Fc free: 0.953 / Occupancy max: 1 / Occupancy min: 0.37 / SU B: 7.77 / SU ML: 0.1 / TLS residual ADP flag: LIKELY RESIDUAL / 交差検証法: THROUGHOUT / σ(F): 0 / ESU R: 0.138 / ESU R Free: 0.126 立体化学のターゲット値: MAXIMUM LIKELIHOOD WITH PHASES 詳細: 1. HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. 2. ATOM RECORDS CONTAIN RESIDUAL B FACTORS ONLY. 3. A MET-INHIBITION PROTOCOL WAS USED FOR SELENOMETHIONINE INCORPORATION DURING PROTEIN ...詳細: 1. HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. 2. ATOM RECORDS CONTAIN RESIDUAL B FACTORS ONLY. 3. A MET-INHIBITION PROTOCOL WAS USED FOR SELENOMETHIONINE INCORPORATION DURING PROTEIN EXPRESSION. THE OCCUPANCY OF THE SE ATOMS IN THE MSE RESIDUES WAS REDUCED TO 0.75 FOR THE REDUCED SCATTERING POWER DUE TO PARTIAL S-MET INCORPORATION. 4. ELECTRON DENSITY INDICATES THAT THE PEPTIDE BOND BETWEEN CYS 332 AND TRP 333 IN BOTH SUBUNITS IN THE ASYMMETRIC UNIT IS IN THE CIS-CONFIGURATION. THIS IS IN THE VICINITY OF THE PUTATIVE ACTIVE SITE. 5. 1,2-ETHANEDIOL (EDO) FROM THE CRYOPROTECTION CONDITION HAS BEEN MODELED IN THE SOLVENT STRUCTURE.
Rfactor
反射数
%反射
Selection details
Rfree
0.205
3384
5.1 %
RANDOM
Rwork
0.169
-
-
-
obs
0.171
66817
99.97 %
-
溶媒の処理
イオンプローブ半径: 0.8 Å / 減衰半径: 0.8 Å / VDWプローブ半径: 1.2 Å / 溶媒モデル: MASK